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Abstract
Health-related quality of life (HRQL) assessment is an important measure of the impact of the
disease, effect of treatment and other variables affecting people's lives. The review focused on the
assessment of HRQL in patient with coronary heart disease (CHD) by appropriate tools. Although
no consensus exists about the precise definition of HRQL, a plethora of instruments have been
developed to assess it. Two broad types – generic and disease-specific – have been developed but
there is some debate about their relative merits. There is a wide selection of instruments available
but choice should be based on a careful consideration of an instrument's psychometric properties,
the breadth and depth with which it addresses relevant health domains and the specific clinical or
research purpose for which it is intended.
Introduction
There has been a rapid and significant growth in the meas-
urement of quality of life as an indicator of health out-
come in patients with coronary heart disease (CHD). In
the clinical course of CHD, there are many aspects where
patients' quality of life may be affect which include symp-
toms of angina and heart failure, limited exercise capacity
of the aforementioned symptoms, the physical debility
caused, and psychological stress associated with the
chronic stress. Modern treatments nowadays focus not
only on improving life expectancy, symptoms and func-
tional status, but also quality of life. Thus, an improve-
ment in health-related quality of life (HRQL) is
considered to be important as a primary outcome and in
the determination of therapeutic benefit [1–3]. This arti-
cle will provide an overall view of how to assess HRQL,
and the tools available for patients with CHD.
Health-related quality of life
Despite the widespread use of the phrase, there is no con-
sensus on the definition of the concept of HRQL, though
definitions usually refer to physical, emotional and social
well-being. HRQL is a distinct construct which refers to
the impact that health conditions and their symptoms
have on an individual's quality of life, and, in the context
of healthcare, the term HRQL is preferred over quality of
life because the focus is on health. It provides a common
benchmark against which can be measured the impact of
different experiences and treatments for the same condi-
tion or the impact of different treatments across different
conditions [4]. As a consequence, HRQL instruments have
evolved in order to assess the impact of disease, effect of
treatment and other variables affecting people's lives.
They provide an assessment of the patient's experience of
his or her health problems in areas such as physical func-
tion, emotional function, social function, role perform-
ance, pain and fatigue. Thus, HRQL can be defined as
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health status and viewed as a continuum of increasingly
complex patient outcomes: biological/physiological fac-
tors, symptoms, functioning, general health perceptions
and overall wellbeing or quality of life [5].
While healthcare professionals may be more interested in
changes in objective physical measures, patients (and
family members/carers) equally interested in a therapy
that changes their symptoms, physical function and social
roles. HRQL instruments measure the effects of treatment
on aspects where patients are continuously concerning
about. Because these instruments describe or characterize
what the patient has experienced as a result of healthcare,
they are useful and important supplements to traditional
physiological or biological measures of health status [5].
Measurement of health-related quality of life
When measuring HRQL it is important that the instru-
ment selected measures the health dimensions relevant to
that particular set of patients [5,6]. For instance, an instru-
ment intended for use with patients after myocardial inf-
arction (MI) should take into account the individual's
responses to living with the disease, in terms of recrea-
tional, occupational, social, personal and sexual relation-
ships, as well as the acute and chronic physical
consequences of the disease [7]. This is because when
someone becomes ill almost all aspects of his or her life
may be affected [8].
HRQL instruments are either 'generic' or 'disease-specific'
(Table 1). Generic instruments address multiple aspects of
quality of life across a range of different patient or disease
groups. Thus, they focus on general issues of health (or ill
health) rather than specific features of a particular disease:
the role of disease-specific instruments. Because disease-
specific instruments comprise content specific to the dis-
ease in question they are more clinically sensitive and
potentially more responsive in detecting change. Each
type has its own particular strengths and weaknesses and
there is some merit in combining both.
When selecting a HRQL instrument, an important issue is
how well it will perform in providing the most appropri-
ate and required information [9]. Thus, its psychometric
properties (reliability and validity) should be examined
[6,8]. Reliability of an instrument is normally assessed in
two ways: internal consistency and test-retest reliability.
The former is an estimate of homogeneity of items meas-
uring a specific health domain and is normally measured
using Cronbach's alpha coefficient. The closer the coeffi-
cient is to 1, the greater the homogeneity between the
items and, therefore, the greater the confidence that can
be attributed that items relate to the domain under inves-
tigation. However, caution should be noted as alpha coef-
ficients of >0.95 can mean that several of the items are in
fact measuring the same thing [6,10].
Test-retest reliability is a measure of an instrument's abil-
ity to produce data that are consistent or stable over time.
It is normally determined using Cohen's Kappa or Pear-
son's or Spearman's correlation coefficient. Normally, lev-
els in excess of 0.6 indicate an adequate test-retest
reliability [6,10].
Validity refers to the ability of a measure to quantify the
item or dimension it is supposed to measure. It should
have various forms of validity. Criterion validity refers to
comparable results using other instruments measuring the
same variable. Content validity is the appropriateness of
items to the purpose of the instrument. Face validity rep-
resents being consistent with current knowledge and
expert opinion. Construct validity is the ability of the
instrument to be sensitive to different levels of quality of
life in a variety of patient groups. Discriminative validity
is the instrument's ability to detect changes in the
observed variable without provoking a 'floor' or 'ceiling'
effect that reflects an inability to detect clinically signifi-
cant changes at the lower or higher spectrum of quality of
life.
Both reliability and validity are not one-time-only
attributes: they need to be re-established when the instru-
ment is used in a different population or culture.
Table 1: Validated instruments available for the assessment of health-related quality of life in patients with coronary heart disease.
Generic Disease-specific
Sickness Impact Profile Seattle Angina Questionnaire
Medical Outcomes Study 36-Item Short Quality of Life after Myocardial
Form Health Survey (SF-36) Infarction questionnaire / MacNew questionnaire
Minnesota Living with Heart Failure questionnaire
Myocardial Infarction Dimensional Assessment Scale (MIDAS)
Cardiovascular Limitations and Symptoms Profile (CLASP)Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/42
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Generic instruments
A number of generic instruments are commonly used in
research and clinical evaluation in populations with
CHD. The two most commonly used ones are the Sickness
Impact Profile [11] and the Medical Outcomes Study 36-
Item Short Form Health Survey [12].
Sickness Impact Profile (SIP)
The SIP [11] comprises 136 items relating to 12 'domains'
of health (mobility, ambulation, domestic affairs, social
interaction, behaviour, communication, recreation, eat-
ing, work, sleep, emotions and self-care). It is thus a
broadly applicable instrument that measures a variety of
health outcomes, including serial changes in wellbeing
over time. The SIP can be interviewer- or self-administered
and offers a comprehensive means of assessing wellbeing,
but its relatively long length can be a disadvantage. How-
ever, it has been recommended as an appropriate generic
measure in angina and MI patients [12,13].
Medical Outcomes Study 36-Item Short Form Health 
Survey (SF-36)
The SF-36 [14] comprises 36 items covering eight
'domains' (physical functioning, social functioning, phys-
ical impairment, emotional impairment, emotions, vital-
ity, pain and global health). The SF-36 is a self-
administered instrument which takes about 15 minutes to
complete. Abbreviated forms, the SF-12 and now the SF-
8, are also available and widely used, taking even less time
to complete. The SF-36 has been used in angina, MI [15]
and heart failure. However, although some reports suggest
that the SF-12 is preferable to the SF-36 because of its
brevity and acceptability to CHD patients [16], some stud-
ies in acute MI patients have found that the SF-12 scores
obscure important distinctions between domains [17]. In
patients with recent MI, SF-36 has been shown to be a sen-
sitive tool for detecting improvement of HRQL after active
intervention [18–20].
Disease-specific instruments
A number of instruments have been designed to examine
specifically the impact of angina, MI or heart failure on
quality of life. Examples include the Seattle Angina Ques-
tionnaire [21], the Quality of Life after Myocardial Infarc-
tion [22–27] questionnaire (now called the MacNew [25]
questionnaire) and Minnesota Living with Heart Failure
[28] questionnaire.
Seattle Angina Questionnaire (SAQ)
The SAQ [21] is a psychometrically solid disease-specific
instrument designed to assess the functional status of
patients with angina. It comprises 19 questions that quan-
tify five clinically relevant domains: physical limitation,
anginal stability, anginal frequency, treatment satisfaction
and disease perception/quality of life. It is often used as a
HRQL instrument because seven of its 19 items relate to
emotional health.
Quality of Life after Myocardial Infarction (QLMI/
MacNew) questionnaire
The original version of the QLMI [22] was designed to be
interview-administered and developed to evaluate the
effectiveness of a comprehensive cardiac rehabilitation
programme. A slightly modified 26-item self-adminis-
tered version has been used [23,24]. This questionnaire
has been validated.[24,25] More recently, an improved
27-item version of the instrument, the MacNew heart dis-
ease questionnaire (sometimes known as the QLMI-2)
has been reported [26]. A good deal of research is being
conducted with this instrument and reference data for
users is now available [27].
Minnesota Living with Heart Failure (MLHF) questionnaire
The MLHF [28] comprises 21 items with a range of
responses from no, very little to very much to produce a
range of scores from 0 (no disability) to 105 (maximal
disability) in relation to signs and symptoms typical of
heart failure, physical activity, social interaction, sexual
activity, work and emotions. The reliability and validity of
the MLHF are sound and it appears sensitive to changes in
treatment, and thus the instrument is used extensively in
studies of heart failure.
Recent reviews have critically examined commonly used
generic and disease-specific HRQL instruments in patients
with CHD [12,13,29–32]. All the generic instruments
studied appeared to have measurement idiosyncrasies.
For example, it was recommended [30] that the SIP
should only be used to obtain total domain scores and
should not be separated into its component scales. The SF-
36 appears to achieve the best results, having fewer floor
or ceiling effects, good internal consistency and a high
test-retest reliability [30].
In terms of disease-specific measures, the SAQ and MLHF
seem to perform well. For instance, in angina the SAQ
appears more sensitive and easier to use by both patients
and investigators than was the SF-36 [29]. The MacNew
(QLMI-2) has had mixed reviews [30,32], though it role
has been affirmed in patients with myocardial infarction
and angina. Its role in patients with heart failure also
showed preliminary promise.
Two recent disease-specific instruments of interest are the
Myocardial Infarction Dimensional Assessment Scale [33]
and the Cardiovascular Limitations and Symptoms Profile
[34].Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/42
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Myocardial Infarction Dimensional Assessment Scale 
(MIDAS)
The MIDAS [33] is an interviewer- or self-administered
questionnaire than comprises 35 items covering seven
areas of health status (physical activity, insecurity, emo-
tional reaction, dependency, diet, concerns over medica-
tions and side effects). The instrument has only recently
been developed and validated in the UK and further
research on its utility is being conducted.
The disease-specific instruments reviewed have been
developed specifically for patients with angina, MI or
heart failure. However, many patients with CHD have sev-
eral of these diagnoses. It has also been pointed out that
patients with CHD usually have other co-morbid condi-
tions which generic instruments may not sufficiently
detect important changes [32,35]. Thus, there is a need for
a disease-specific (for CHD) instrument to address this
issue.
Cardiovascular Limitations and Symptoms Profile (CLASP)
The CLASP [34] comprises 37 items that yield four symp-
toms subscales (angina, shortness of breath, ankle swell-
ing and tiredness) and five functional limitation subscales
(mobility, social life and leisure activities, activities within
the home, concerns and worries and gender). Each sub-
scale has four to six questions and scores are weighted to
provide a total for each subscale (normal or mild to
severe). The CLASP has been validated in patients with
chronic stable angina and further research is required
before it can be recommended for routine use.
One of the difficulties facing researchers and clinicians in
the assessment of HRQL is the selection of instruments:
generic or disease-specific. A recent review has concluded
that, overall, disease-specific instruments of HRQL are
more responsive than generic ones [36]. New instruments
and novel methods for measuring HRQL in patients with
CHD are being developed at a rapid rate. For example,
individualized instruments, such as the Patient Generated
Index [32], appear promising even though they are in
their early stage of development.
Conclusions
HRQL represents the effect of an illness and its treatment
as perceived by the patient and plays an important role as
a primary outcome measure. There is a wide selection of
instruments available but choice should be based on a
careful consideration of psychometric properties, rele-
vance and suitability. It should be emphasized that many
instruments currently available are rather cumbersome
and time-consuming for routine application in clinical
practice. There is a need for simple instruments that are
responsive, easily applied and rapidly interpreted.
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